EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

Éabha O'Sullivan iD, Anna Keogh, Brian Henderson, Stephen P Finn, Steven G Gray, Kathy Gately iD

Cancers · 07.03.2023 · 15 (6) · 1635

DOI: 10.3390/cancers15061635 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.03.2023. Verfasst von Éabha O'Sullivan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Research Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, St. James's Hospital, D08 W9RT Dublin, I…. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activating mutations in KRAS are highly prevalent in solid tumours and are frequently found in 35% of lung, 45% of colorectal, and up to 90% of pancreatic cancers. Mutated KRAS is a prognostic factor for disease-free survival (DFS) and overall survival (OS) in NSCLC and is associated with a more aggressive clinical phenotype, highlighting the need for KRAS-targeted therapy. Once considered undruggable due to its smooth shallow surface, a breakthrough showed that the activated G12C-mutated KRAS isozyme can be directly inhibited via a newly identified switch II pocket. This discovery led to the development of a new class of selective small-molecule inhibitors against the KRAS G12C isoform. Sotorasib and adagrasib are approved in locally advanced or metastatic NSCLC patients who have received at least one prior systemic therapy. Currently, there are at least twelve KRAS G12C inhibitors being tested in clinical trials, either as a single agent or in combination. In this study, KRAS mutation prevalence, subtypes, rates of occurrence in treatment-resistant invasive mucinous adenocarcinomas (IMAs), and novel drug delivery options are reviewed. Additionally, the current status of KRAS inhibitors, multiple resistance mechanisms that limit efficacy, and their use in combination treatment strategies and novel multitargeted approaches in NSCLC are discussed.

Schlagwörter

Stichwörter der Autor:innen

ACOX2BRAFG12C mutationIMAsKRASNSCLCadagrasibdrug resistancesotorasib

Autor:innen und Institutionen

  • Thoracic Oncology Research Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, St. James's Hospital, D08 W9RT Dublin, Ireland.
  • Thoracic Oncology Research Group, Laboratory Medicine and Molecular Pathology, Central Pathology Laboratory, St. James's Hospital, D08 RX0X Dublin, Ireland.

ORCID-Profile: Éabha O'Sullivan, Kathy Gately

Zitieren

APA

O'Sullivan, É., Keogh, A., Henderson, B., Finn, S. P., Gray, S. G., & Gately, K. (2023). Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer. Cancers, 15(6), 1635. https://doi.org/10.3390/cancers15061635

Vancouver

O'Sullivan É, Keogh A, Henderson B, Finn SP, Gray SG, Gately K. Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer. Cancers. 2023;15(6):1635. doi:10.3390/cancers15061635

BibTeX
@article{OSullivan2023,
  author = {O'Sullivan, Éabha and Keogh, Anna and Henderson, Brian and Finn, Stephen P and Gray, Steven G and Gately, Kathy},
  title = {Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {6},
  pages = {1635},
  doi = {10.3390/cancers15061635}
}
Kostenlos starten →